Attached files

file filename
EX-99 - EXHIBIT 99.1 - Furiex Pharmaceuticals, Inc.ex99-1.htm
EX-99 - EXHIBIT 99.2 - Furiex Pharmaceuticals, Inc.ex99-2.htm

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

 

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported) May 6, 2014

 

FURIEX PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware

(State or other jurisdiction of incorporation)

 

001-34641

 

27-1197863

(Commission File Number)

 

(IRS Employer ID Number)

                 

3900 Paramount Parkway, Suite 150, Morrisville, North Carolina 27560

(Address of principal executive offices) (Zip Code)

 

Registrant's telephone number, including area code (919) 456-7800

__________________

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 
 

 

 

Item 2.02. Results of Operations and Financial Condition.

 

On May 7, 2014, Furiex Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its operating results for the quarter ended March 31, 2014. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein in its entirety by reference.

 

The information in Item 2.02 of this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

 

Item 8.01. Other Events.

 

Attached hereto as Exhibit 99.2 and incorporated herein by reference is the May 6, 2014 late-breaker presentation at Digestive Disease Week on eluxadoline for the treatment of diarrhea-predominant irritable bowel syndrome.

 

Item 9.01. Financial Statements and Exhibits.

 

(d)     Exhibits.

 

Exhibit No.

Description

 

 

99.1

Press release issued May 7, 2014, announcing operating results for the quarter ended March 31, 2014.

 

 

99.2

Presentation on May 6, 2014, regarding eluxadoline.

           

 
 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

FURIEX PHARMACEUTICALS, INC.

 

 

 

 

 

Date: May 7, 2014

 

 

 

 

By:

/s/ Sailash I. Patel

 

 

 

Sailash I. Patel

 

 

 

Chief Financial Officer and Vice President Strategic Development